MX2022013174A - Semaglutida para el tratamiento de la esteatohepatitis no alcoholica. - Google Patents

Semaglutida para el tratamiento de la esteatohepatitis no alcoholica.

Info

Publication number
MX2022013174A
MX2022013174A MX2022013174A MX2022013174A MX2022013174A MX 2022013174 A MX2022013174 A MX 2022013174A MX 2022013174 A MX2022013174 A MX 2022013174A MX 2022013174 A MX2022013174 A MX 2022013174A MX 2022013174 A MX2022013174 A MX 2022013174A
Authority
MX
Mexico
Prior art keywords
treatment
semaglutide
alcoholic steatohepatitis
glp
directed
Prior art date
Application number
MX2022013174A
Other languages
English (en)
Inventor
Martin Linder
Mads Sundby Palle
Lars Holm Damgaard
Morten Hansen
Carl Richard Torstenson
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2022013174A publication Critical patent/MX2022013174A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La presente invención se dirige al uso del agonista del receptor de GLP-1 semaglutida en la terapia médica para el tratamiento de la esteatohepatitis no alcohólica.
MX2022013174A 2020-04-27 2021-04-26 Semaglutida para el tratamiento de la esteatohepatitis no alcoholica. MX2022013174A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20171536 2020-04-27
EP20173341 2020-05-06
PCT/EP2021/060827 WO2021219543A1 (en) 2020-04-27 2021-04-26 Semaglutide for the treatment of non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
MX2022013174A true MX2022013174A (es) 2022-11-30

Family

ID=75660049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013174A MX2022013174A (es) 2020-04-27 2021-04-26 Semaglutida para el tratamiento de la esteatohepatitis no alcoholica.

Country Status (13)

Country Link
US (3) US11478533B2 (es)
EP (1) EP4142770A1 (es)
JP (1) JP7393563B2 (es)
KR (1) KR20230015884A (es)
CN (1) CN115461072A (es)
AU (1) AU2021262447A1 (es)
BR (1) BR112022020643A2 (es)
CA (1) CA3174964A1 (es)
CL (1) CL2022002813A1 (es)
IL (1) IL297273A (es)
MX (1) MX2022013174A (es)
TW (1) TW202140064A (es)
WO (1) WO2021219543A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115484972A (zh) 2020-04-24 2022-12-16 勃林格殷格翰国际有限公司 作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
TW202333774A (zh) * 2021-12-01 2023-09-01 大陸商江蘇恆瑞醫藥股份有限公司 Glp-1和gip受體雙重激動劑的醫藥組成物及其用途
CN114469877A (zh) * 2022-01-28 2022-05-13 兰州积石药业有限公司 一种司美格鲁肽植入剂及其制备方法
WO2024017139A1 (zh) * 2022-07-20 2024-01-25 成都海博为药业有限公司 一种含有glp-1受体激动剂类似物的药物组合物

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
WO2001092206A1 (en) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Method of preparing salicylamides
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
HUE038395T2 (hu) 2003-11-20 2018-10-29 Novo Nordisk As Propilén-glikol tartalmú peptidkészítmények, amelyek elõállításra és injekciós eszközökben történõ alkalmazásra optimálisak
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
BRPI1013639A2 (pt) 2009-02-13 2016-04-19 Boehringer Ingelheim Int medicamentos antidiabéticos
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
PE20161219A1 (es) 2011-11-11 2016-11-17 Pfizer 2-tiopirimidinonas
TWI701253B (zh) 2011-11-11 2020-08-11 美商基利阿波羅有限責任公司 Ａｃｃ抑制劑及彼等之用途
CA2869587A1 (en) 2012-04-06 2013-10-10 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
CA2911822A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
BR112015028152A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
EA201591959A1 (ru) 2013-05-10 2016-03-31 Нимбус Аполло, Инк. Ингибиторы акк и их применение
US9765089B2 (en) 2013-05-10 2017-09-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
SI3119757T1 (en) 2014-03-17 2018-08-31 Pfizer Inc. DIACILGLICEROL-ACILTRANSFERAZE 2 BINDERS FOR THE USE IN THE TREATMENT OF PRECIOUS AND RELATED DISEASES
CA2962572A1 (en) 2014-09-24 2016-03-31 Gilead Sciences, Inc. Methods of treating liver disease with a combination of an ask1 inhibitor and a fxr agonist
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
CA2972919A1 (en) 2015-01-09 2016-07-14 Gilead Apollo, Llc Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
JP2019504106A (ja) 2015-10-28 2019-02-14 タフツ ユニバーシティー タンパク質分解安定性が改善された新規ポリペプチド並びにその調製方法及び使用方法
BR112018010113B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Composto de pirazol útil como inibidor da acetil-coa carboxilase (acc)
KR20180082557A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 트리아졸 acc 억제제 및 그의 용도
CA3004798C (en) 2015-11-25 2023-10-31 Gilead Apollo, Llc Ester acc inhibitors and uses thereof
KR20180086191A (ko) 2015-11-25 2018-07-30 길리어드 아폴로, 엘엘씨 2,4-디옥소-1,4-디히드로티에노[2,3-d]피리미딘 유도체를 함유하는 살진균 조성물
CA3220447A1 (en) 2016-03-02 2017-09-08 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
JP2019519478A (ja) 2016-04-19 2019-07-11 ユレカ・ソシエテ・ア・レスポンサビリテ・リミテＵｒｅｋａ Ｓａｒｌ ペプチド−オリゴ尿素フォルダマー化合物及びそれらの使用方法
WO2017205684A1 (en) 2016-05-25 2017-11-30 Akarna Therapeutics, Ltd. Combination therapies with farnesoid x receptor (fxr) modulators
SG11201810602YA (en) 2016-06-03 2018-12-28 Chemocentryx Inc Method of treating liver fibrosis
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
SG11201810600WA (en) 2016-06-13 2018-12-28 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
US10588880B2 (en) 2016-09-28 2020-03-17 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
WO2018071528A1 (en) 2016-10-11 2018-04-19 University Of Georgia Research Foundation, Inc. Proteins and method for treating obesity and associated comorbidities
WO2018089212A1 (en) 2016-11-11 2018-05-17 Gilead Sciences, Inc. Methods of treating liver disease
CA3046158A1 (en) 2017-01-27 2018-08-02 Genfit Pharmaceutical compositions for combination therapy
ES2963841T3 (es) 2017-03-03 2024-04-02 Gilead Sciences Inc Procesos para preparar inhibidores de ACC y formas sólidas del mismo
CN111032680A (zh) 2017-03-15 2020-04-17 诺和诺德股份有限公司 能够与黑皮质素4受体结合的双环化合物
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
CN110475556A (zh) 2017-03-28 2019-11-19 吉利德科学公司 治疗肝疾病的方法
TW201902478A (zh) 2017-04-12 2019-01-16 美商基利科學股份有限公司 治療肝臟疾病之方法
AU2018254743B2 (en) 2017-04-18 2024-04-11 Genfit Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor
US20210198305A1 (en) 2017-06-02 2021-07-01 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018231851A1 (en) 2017-06-13 2018-12-20 Gilead Sciences, Inc. Methods of treating liver fibrosis
EP3655780B1 (en) 2017-07-19 2021-11-10 Bio-Rad Europe GmbH Biomarker combinations to evaluate non-alcoholic steatohepatitis and/or hepatic fibrosis status
US11352405B2 (en) 2017-08-09 2022-06-07 Sanofi GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
AU2018345817B2 (en) 2017-10-06 2021-10-28 Gilead Sciences, Inc. Combination therapy comprising an ACC inhibitor
JP7486423B2 (ja) 2018-01-17 2024-05-17 ユニバーシティ オブ コネチカット 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法
AU2019223911A1 (en) 2018-02-21 2020-07-23 Melior Pharmaceuticals I, Inc. Treatment of liver diseases
WO2019173505A1 (en) 2018-03-06 2019-09-12 Zafgen, Inc. Methods of treating disorders related to glycemic control
US20210069286A1 (en) 2018-04-09 2021-03-11 9 Meters Biopharma, Inc. Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage
WO2019209738A1 (en) 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
BR112020022027A2 (pt) 2018-05-04 2021-02-02 Novo Nordisk A/S derivados de gip e seus usos
WO2019213611A1 (en) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
US11081516B2 (en) 2018-08-10 2021-08-03 Guangdong Oppo Mobile Telecommunications Corp., Ltd. Display screen, electronic device and method for three-dimensional feature recognition
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
ES2954584T3 (es) 2018-10-26 2023-11-23 Novo Nordisk As Composiciones estables de semaglutida y usos de las mismas
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
AU2019378845A1 (en) 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
CN113302190A (zh) 2019-01-15 2021-08-24 吉利德科学公司 Fxr(nr1h4)调节化合物
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
CA3132044A1 (en) 2019-03-11 2020-09-17 Brian Kirby Formulations of a compound and uses thereof
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine

Also Published As

Publication number Publication date
TW202140064A (zh) 2021-11-01
CN115461072A (zh) 2022-12-09
IL297273A (en) 2022-12-01
WO2021219543A1 (en) 2021-11-04
US11478533B2 (en) 2022-10-25
BR112022020643A2 (pt) 2022-12-13
JP7393563B2 (ja) 2023-12-06
US20240075106A1 (en) 2024-03-07
JP2023516505A (ja) 2023-04-19
US20230023012A1 (en) 2023-01-26
AU2021262447A1 (en) 2022-11-03
US20210330748A1 (en) 2021-10-28
EP4142770A1 (en) 2023-03-08
KR20230015884A (ko) 2023-01-31
CL2022002813A1 (es) 2023-04-21
CA3174964A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MX2022013174A (es) Semaglutida para el tratamiento de la esteatohepatitis no alcoholica.
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
MY155255A (en) Spiro-oxindole compounds and their use as therapeutic agents
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
TWD196868S (zh) 超音波治療手持件
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
MX2017013142A (es) Terapia combinada para tratar cáncer.
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
PH12016502353A1 (en) Pharmaceutical composition
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
PH12021550448A1 (en) Chronic nightly dosing of lasmiditan for migraine prevention.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2023004796A (es) Compuestos, composiciones y metodos de uso para tratar fracturas oseas.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2020013601A (es) Receptores de las celulas t especificos de cancer.